Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
Public ClinicalTrials.gov record NCT00313248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients With Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.
Study identification
- NCT ID
- NCT00313248
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2006
- Primary completion
- Sep 30, 2008
- Completion
- Oct 31, 2008
- Last update posted
- Dec 9, 2015
2006 – 2008
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Anchorage | Alaska | 99508 | — |
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Hot Springs | Arkansas | 71913 | — |
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | Palm Springs | California | 92262 | — |
| Not listed | Aurora | Colorado | 80010 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Daytona Beach | Florida | 32114 | — |
| Not listed | Decatur | Illinois | 62526 | — |
| Not listed | New Albany | Indiana | 47150 | — |
| Not listed | Baltimore | Maryland | 21204 | — |
| Not listed | Minneapolis | Minnesota | 55455 | — |
| Not listed | Livingston | New Jersey | 07039 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Syracuse | New York | 13210 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213-3180 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78207 | — |
| Not listed | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00313248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00313248 live on ClinicalTrials.gov.